Peptides for Beginners: Basics and Legal Status

TL;DR: Peptides are short chains of 2 to 50 amino acids. Some, such as GLP-1 agonists or teriparatide, are approved as medicines in the EU/US. Others like BPC-157, TB-500 or epithalon are sold as “research chemicals” and are not approved. The evidence for them is limited, and use in humans is legally problematic. This article covers basics, evidence, risks and legal status and does not recommend any use.

This article is for information only and does not replace medical advice. It contains no recommendation to use peptides. Many peptides are not approved as medicines in the EU. Their use, import and possession can be legally problematic. Intake, dose and treatment belong in a physician’s hands.

What Peptides Actually Are

Peptides are short amino acid chains. Two to 50 amino acids, linked by peptide bonds. Anything longer is called a protein. The cutoff is arbitrary but practical: short chains behave differently than long ones. They cross membranes more easily, bind to specific receptors and act quickly.

The body produces peptides constantly. Insulin from the pancreas is involved in blood sugar regulation. Oxytocin from the pituitary plays a role in bonding, labor and milk ejection. Glucagon raises blood sugar when it drops. ACTH, growth hormone, ghrelin, leptin, vasopressin — all are peptides or peptide hormones.

The distinction matters: endogenous peptides have decades of research, well-characterized receptors and well-described effects. Synthetic peptides mimic these mechanisms or engage adjacent pathways. Some are approved medicines. Many are not.

For an overview of how lab values fit into overall health, the guide to understanding blood values offers context.

Approved vs. Unapproved Peptides

Regulatory status determines availability, quality control, medical prescription and liability. The table below summarizes the most discussed groups.

Approved peptides pass through Phase 1 to 3 studies with thousands of subjects, standardized manufacturing and regulatory oversight. Unapproved peptides have not completed this process. That does not automatically mean they are useless or harmful. It means solid human data on efficacy and safety are missing.

How Peptides Work

Peptides bind to specific receptors on cell surfaces and trigger downstream signaling. Three principles describe most mechanisms.

Receptor agonism. The peptide activates a receptor the way an endogenous signaling molecule would. GLP-1 agonists mimic the intestinal hormone GLP-1 and bind to the GLP-1 receptor in pancreas and brain. They influence blood sugar regulation, slow gastric emptying and act on satiety.

Tissue specificity. Some peptides preferentially act at specific sites. For BPC-157 (Body Protection Compound, isolated from human gastric juice), high affinity for tendon, muscle and gut tissue has been described in animal models. GHK-Cu binds to collagen-producing fibroblasts in skin.

Pathway modulation. Peptides can influence several downstream pathways in parallel. Thymosin-α1 modulates T-cell maturation and innate immune responses. Selank affects GABA and serotonin signaling in the brain.

The practical catch: most BPC-157, TB-500 or epithalon data come from rat and cell culture studies. Human trials are rare, small and often methodologically weak. Claims such as “clinically proven” can only be judged by looking at the cited study.

Research Topics (Evidence, Not Recommendation)

The following areas are discussed in research and in the peptide community. Important: these are theoretical application fields based on preclinical data, not proven indications. None of these uses, outside approved indications, is authorized in the EU. This article makes no recommendation for use.

Regeneration and wound healing. BPC-157 and TB-500 are studied in connection with tendon, ligament and muscle injuries. Animal data describe accelerated healing; human data are sparse.

Metabolism and weight. GLP-1 agonists are approved for type 2 diabetes and obesity, and the evidence from approval trials is extensive. Whether a preparation is appropriate in an individual case is decided by the treating physician based on the indication.

Immune modulation. Thymosin-α1 is approved in some countries, in Italy as an adjuvant to flu vaccination in immunocompromised people. Zadaxin is not approved in Germany or most other EU countries. The evidence is inconsistent.

Cognition and stress. Selank and semax are discussed as nootropics. Russian research literature describes anxiolytic effects; Western human data remain scarce.

Anti-aging and skin. GHK-Cu is established in topical cosmetics. Systemic use is not approved. Epithalon is mentioned in connection with telomerase activation, with thin evidence.

Growth hormone axis. CJC-1295 and ipamorelin are studied in relation to endogenous growth hormone release. Not approved, limited human data.

Across all these areas, clean diagnostics come first, beginning with a structured biomarker baseline.

Why the Form of a Preparation Matters

Peptides are proteins. The stomach digests them like any other protein. This explains why oral uptake is low for many peptides and why approved preparations come in a form developed by the manufacturer and prescribed by a physician.

One example is oral semaglutide (Rybelsus). It uses a carrier molecule (SNAC) to cross the stomach barrier, with roughly 1 percent bioavailability. The literature also describes nasal sprays (for example for oxytocin, selank, semax) and topical creams (GHK-Cu, local action on the skin).

Self-use of injectable products without medical training is particularly risky. Unsterile handling or contaminated material can cause infections and abscesses. This is a task for medically trained people and not a subject for self-experiments.

Legal Status: EU, US, Sports

The regulatory frame is possibly the most important point of this article. It decides whether something is an approved medicine or a product from a grey zone.

EU. Only approved medicines may be marketed and prescribed as such. BPC-157, TB-500, epithalon, selank, semax, melanotan and systemic GHK-Cu are not approved. Vendors label them as “research chemicals” — for laboratory research only, not for human use. Import, possession and trade can have consequences under medicines law.

US. In 2023 the FDA placed several popular peptides (BPC-157, CJC-1295, ipamorelin) on Category 2 of the compounding list. This means compounding pharmacies may no longer dispense them to patients. Grey-market sales as “research chemicals” continue but are legally constrained.

Sport. Many peptides are on the WADA prohibited list. GLP-1 agonists, growth hormone secretagogues (CJC-1295, ipamorelin), thymosin-β4 and BPC-157 are banned for competitive athletes. Positive tests trigger multi-year suspensions.

Approved medicines are prescribed by physicians. For unapproved substances there is no lawful prescribing pathway, and this article makes no recommendation in that regard.

Lab Values in a Medical Context

In a medical work-up, starting values are often collected. Without them it is impossible to judge later whether a change has a specific cause or already existed. The table shows which values typically play a role.

Abnormal changes, especially in liver and kidney values, should be clarified medically. When and how often values are rechecked is decided by the treating physician.

Quality and Testing Outside Approval

Approved medicines are subject to manufacturing and quality requirements (GMP), sterility and purity standards and regulatory oversight. This framework does not apply to unapproved products. Certificates supplied by vendors themselves do not replace approval.

Contamination with bacterial endotoxins, heavy metals or incorrectly synthesized side peptides is documented. Peptides are also heat-sensitive, and an interrupted cold chain can affect the quality of the active ingredient.

Independent laboratory analyses by third parties came to sobering results: a relevant share of tested research-chemical-scene products contained less active ingredient than labeled or showed contamination.

Risks and Open Questions

Evidence for most unapproved peptides is thin. Six points feature prominently in the expert discussion.

Lack of long-term studies. For BPC-157, TB-500, epithalon and others there are no human studies beyond 12 months. What happens at 5 or 10 years is unknown. Peptides interfere with cell growth and receptor signaling — time horizons matter.

Tumor growth. Growth-promoting peptides (GHK-Cu, BPC-157, growth hormone peptides) could theoretically accelerate existing tumors. Preclinical data are mixed, clinical relevance is unclear. With a cancer history, this is a point physicians weigh with particular care.

Immune reactions. Synthetic peptides can trigger antibody responses. This can weaken the effect and cause allergic or autoimmune reactions.

Injection risks. Abscesses, infections, granulomas, lipohypertrophy at the injection site. Unsterile work dramatically increases risk.

Quality problems. Contamination with bacterial endotoxins, heavy metals or incorrectly synthesized side peptides. Without regulatory approval there is no quality guarantee.

Legal consequences. Import, possession and resale of unapproved substances can have consequences under customs and medicines law.

For these reasons, any consideration of peptides belongs in medical hands. Trend data from regular biomarker tracking can support the conversation with a physician.

Perspective: Medical Use and Self-Use

The peptide community is split. On one side are medical users with a prescription — mostly GLP-1 agonists for obesity or teriparatide for osteoporosis. On the other side are people who use unapproved substances such as BPC-157 or epithalon on their own.

The two groups have different risk profiles. The medical path offers quality control, medical supervision and liability. This safety net is missing on the path via unapproved products.

The ethical assessment is individual. Legally and medically, self-use of unapproved substances remains risky, even when accompanied by baseline data. For any weighing of risk, benefit and legal situation, medical advice is the right place.

Peptides in Context With Other Factors

Peptides are not a standalone fix. Sleep, nutrition, training and recovery form the frame in which lab values are understood. Three connections are particularly relevant.

Peptides and base labs. Liver and kidney values are among the first values a physician looks at. The articles on liver values and kidney values provide context.

Peptides and supplements. For dietary supplements in general, the supplement beginners guide offers orientation. Here too, intake and interactions belong with a physician.

Peptides and behavior change. GLP-1 agonists are examined in studies in connection with nutrition and physical activity. It is reported that weight loss often returns after stopping.

Conclusion: Between Medicine and Grey Zone

Peptides are among the most interesting substance classes of the coming years. GLP-1 agonists play an important role in obesity medicine, and teriparatide is approved for severe osteoporosis. At the same time, a grey market for research chemicals is growing — legally, medically and ethically problematic.

Three points for orientation:

1. Diagnostics before any consideration. A clean starting point with liver, kidney, blood count and hormone values is the basis of any medical assessment.
2. Medical clarification. Approved peptides are prescribed by physicians. For everything else the legal and medical framework is missing.
3. Documentation. Trend tracking over 12 months says more than any single measurement.

The biomarker baseline checklist shows which values can be documented digitally. The features of Lab2go support structured tracking of lab values, and the plans and pricing give an overview of the options.

This article is for information only and does not replace medical advice. It contains no recommendation to use peptides. In the EU, many peptides are not approved as medicines and human use is legally problematic. Intake, dose and treatment belong exclusively in a physician’s hands.